Survival benefits were maintained among those with brain metastases.
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
The FDA has accepted for Priority Review the New Drug Application (NDA) for tucatinib (Seattle Genetics), in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
BMI had no impact on progression-free survival to first-line chemotherapy.
CMS recently announced that patients with germline ovarian or breast cancer would be covered for diagnostic testing that uses next-generation sequencing.
A SABCS 2019 session encouraged oncologists to scrutinize whether presentations are practice changing, and included a look at controversial data from KEYNOTE-522.
The cancer field is not immune to the challenges of out-of-network and surprise billing.
Content was developed by PRI Healthcare Solutions, a division of Haymarket Media, Inc. Advertising support received from Seattle Genetics, Inc. Seattle Genetics, Inc. did not influence or provide oversight over content. In this video, breast medical oncologist, Carey Anders, MD, medical director of the Duke Center for Brain and Spine Metastasis at the Duke…
The tool is still diagnostically useful in both cases, it just may require sex-specific guidelines for use.
Clinicians should be prepared to discuss limited data for benefit of endocrine tx in ER-low positive cases.
The ASCO/CAP Expert Panel continues to recommend IHC as the only primary screening test for predicting benefit of endocrine therapy in breast cancer.
The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
Almost half of higher stage of disease at diagnosis in racial/ethnic minorities explained by insurance status.
Women with lower education may be less likely to gain awareness of breast density due to the laws.
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
Cardio-oncology is an emerging field focusing on the detection, monitoring, and treatment of cardiac dysfunction related to systemic or radiation therapy.
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.